Biodesix INC Form 4 insider transactions

Director Charles M. Watts reported a transaction involving Biodesix Inc. common stock and restricted stock units on April 1, 2024.

Chris Vazquez, Chief Accounting Officer of Biodesix Inc., acquired 14,280 stock options on February 21, 2024, as part of the company's 2023 Bonus-to-Options Program.

Gary Anthony Pestano, Chief Development Officer of Biodesix Inc., acquired 3,690 stock options on February 21, 2024, as part of the company's Bonus-to-Options Program.

Kieran O'Kane, Chief Commercial Officer of Bio-Rad Laboratories, acquired 35,307 stock options on February 21, 2024, as part of the company's Bonus-to-Options Program.

Biodesix CEO Scott Hutton acquired 180,926 stock options on February 21, 2024, as part of the company's 2023 Bonus-to-Options Program.

Robin Harper Cowie, CFO, Sec'y & Treasurer of BIODESIX INC, acquired 62,358 stock options on February 21, 2024, as part of the company's 2023 Bonus-to-Options Program.